NuCana stock slips 4.3% as bearish momentum builds ahead of earnings

Traders Union
All News
Financial News
NuCana slides 4.30% to $1.78 today

Highlights

NuCana is set to report quarterly results on March 19, with analysts forecasting a per-share loss of ($2.6944).
The company advances its ProTide platform to improve solid tumor therapies, but shares remain under prolonged selling pressure.
NCNA trades well below key moving averages, with bearish momentum indicators and is likely to consolidate between $1.73 and $1.89 short-term.

Earnings loss expected as broad selling pressure persists

NuCana is expected to report its quarterly earnings results before the market opens on March 19, with analysts anticipating a loss of ($2.6944) per share. The company continues to develop enhanced nucleoside analogues using its proprietary ProTide platform. Its research focuses on improving therapies for patients with solid tumor indications, though price action has remained under broader selling pressure.

Bearish momentum holds below key moving averages and resistance

The technical setup for NCNA confirms a bearish outlook, with the price sitting below all major moving averages. Immediate resistance is defined by the Ichimoku Kijun level at $2.08. Bearish momentum is indicated by both MACD (Strong Sell) and an ADX value of 30.15, while oscillators such as RSI (34.26) and CCI (-165.85) reflect oversold conditions. Stoch RSI is neutral but leaning low, and BBP remains negative, all pointing to persistent seller dominance in the current session.

Directional risk skews lower amid lack of reversal signals

Near term, NCNA is expected to fluctuate within a volatility band relative to current levels, between $1.73 and $1.89 over the coming week. With no buy signals from the weekly MA-50, RSI, ADX, or MACD, the likelihood of upward price movement remains low, at less than 20%. A break above resistance at $2.08 would be required to activate a bullish scenario, while a drop below $1.73 could lead to further declines given prevailing bearish momentum.

Anton Kharitonov, expert at Traders Union, sees NuCana’s technical outlook as heavily bearish with the price stuck below all major moving averages and persistent selling pressure. He notes the upcoming earnings report and ongoing drug development do little to offset current weakness, as key indicators point to continued dominance by sellers. Kharitonov believes the likelihood of a rebound remains low until resistance at $2.08 is reclaimed. "Base case remains further downside unless NCNA can break back above $2.08 — for now, defensive positioning is justified."

Previously it was reported that NuCana shares were under sustained technical pressure, with bearish momentum dominating across all timeframes. The current setup further reinforces this outlook, with traders advised to monitor $1.73 as a critical support level amid heightened volatility and a continued lack of bullish signals.

Source of Data: NCNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.